radius health inc (RDHE:OTC BB)

Executive Profile*

Background*

Dr. Cecil Richard Edmund Lyttle, Ph.D has been consultant of Radius Health, Inc. (also known as NuVios, Inc) since June 4, 2012 and served as its Chief Scientific Officer of from December 2011 to June 4, 2012 and served as its President and Chief Executive Officer since October 4, 2004. Prior to Radius Health, Dr. Lyttle directed drug discovery in women's health at Wyeth in the areas of menopause, contraception, reproductive disorders, osteoarthritis, osteoporosis, and ... urinary incontinence. Under his leadership, Wyeth advanced 17 new product candidates into preclinical and clinical development, including the SERM, bazedoxifene, currently in Phase III clinical trials; Tanaproget, a novel non-steroidal contraceptive; and DVS-233 for vasomotor symptoms associated with menopause. Prior to Wyeth, Dr. Lyttle was Professor of Obstetrics & Gynecology, and Pharmacology at the University of Pennsylvania. He has been a Director of MPM Acquisition Corp. since November 22, 2010. He has been Chairman of Scientific Advisory Board at Radius Health, Inc. since June 4, 2012. He served as a Director of Radius Health, Inc. He received a PhD in Biochemistry from Queen's University, Kingston, Ontario, followed by postdoctoral research at the Population Council at the Rockefeller University and at the Ben May Laboratory for Cancer Research at the University of Chicago.

Report Data Issue

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Recently Viewed
RDHE:US	$0.00 USD	0.00

COMPETITOR COMPENSATION